Elicio Therapeutics, Inc. (ELTX)
(Delayed Data from NSDQ)
$4.60 USD
-0.28 (-5.74%)
Updated Oct 4, 2024 01:15 PM ET
After-Market: $4.62 +0.02 (0.43%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Elicio Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 14 | 50 | 89 | 35 | 6 |
Receivables | 0 | 0 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 1 | 2 | 8 | 0 |
Total Current Assets | 16 | 51 | 91 | 42 | 6 |
Net Property & Equipment | 1 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 1 | 1 | 1 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 0 | 0 | 0 | 0 |
Total Assets | 27 | 53 | 97 | 47 | 12 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 51 | 6 |
Accounts Payable | 4 | 3 | 5 | 6 | 11 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 3 | 3 | 7 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 2 | 43 | 6 |
Total Current Liabilities | 10 | 6 | 11 | 107 | 27 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 26 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 16 | 9 | 15 | 138 | 30 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 154 | 297 | 296 | 72 | 64 |
Retained Earnings | -142 | -254 | -215 | -161 | -80 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 2 | 2 |
Total Shareholder's Equity | 11 | 44 | 82 | -90 | -19 |
Total Liabilities & Shareholder's Equity | 27 | 53 | 97 | 47 | 12 |
Total Common Equity | 11 | 44 | 82 | -90 | -19 |
Shares Outstanding | 8.40 | 3.00 | 3.00 | NA | NA |
Book Value Per Share | 1.35 | 14.59 | 27.17 | 0.00 | 0.00 |
Fiscal Year End for Elicio Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 4 | 13 | 14 | 17 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 2 | 3 | 3 |
Total Current Assets | NA | 7 | 14 | 16 | 20 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 3 | 4 | 4 |
Total Assets | NA | 16 | 24 | 27 | 31 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 4 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 5 | 3 | 4 | 4 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 1 | 2 |
Total Current Liabilities | NA | 8 | 6 | 10 | 11 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 8 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 17 | 20 | 16 | 18 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 160 | 159 | 154 | 147 |
Retained Earnings | NA | -161 | -154 | -142 | -133 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -2 | 5 | 11 | 13 |
Total Liabilities & Shareholder's Equity | NA | 16 | 24 | 27 | 31 |
Total Common Equity | 0 | -2 | 5 | 11 | 13 |
Shares Outstanding | 10.70 | 10.20 | 10.20 | 8.40 | 8.30 |
Book Value Per Share | 0.00 | -0.16 | 0.48 | 1.35 | 1.60 |